Loading clinical trials...
Loading clinical trials...
Hormonal Contributors to Coronavirus SARS-CoV-2 Infection (COV-ENDO)
The goal of this observational study is to measure the changes in the parameters of endocrine function and tissue sensitivity to hormones induced by SARs-CoV-2 infection. The main questions it aims to answer are: * Does SARs-CoV-2 infection causes endocrine dysfunctions? * Does the treatment of the underlying endocrine dysfunctions, improves the clinical outcome or the occurrence of late onset complications of SARs-CoV-2 infection? * Are patients with previously known endocrine diseases more fragile in case of SARs-CoV-2 infection? Participants will undergo blood testing and a physical examination at admission, during hospitalization at discharge and 3 and 6 moths after discharge They results will be compared to those of patients admitted for other reasons in order to assess whether the prevalence of endocrine dysfunctions is increased compared with controls.
The objectives of the study are the following: Primary objectives: 1. to measure endocrine function tests in patients affected by COVID-19, in order to evaluate whether SARs-CoV-2 causes endocrine alterations and whether endocrine diseases/dysfunctions correlate with the severity of SARs-CoV-2 infection and mortality. 2. to evaluate whether genetic variants in the sex-steroid or vitamin D (VDR) nuclear receptors or ACE are more prevalent in patients with SARs-CoV-2 infection than controls. 3. to evaluate whether vitamin D supplementation in subjects with vitamin D deficiency may influence the outcome of SARs-CoV-2 infection 4. To correlate the influence of overweight/obesity/neck circumference with the evolution of SARs-CoV-2 infection Secondary objectives: Correlate the endocrine function tests with patients' age, disease's outcome, markers of inflammation. The identification of endocrine conditions associated with a worse outcome of SARs-CoV-2 infection, would identify significant risk factors to be reduced/prevented in these patients. For example, if endocrine patients will result more fragile in case of infection, we could systematically screen some parameters and early treat associated defects in order improve the outcome of SARs-CoV-2 infection.
Age
18 - No limit years
Sex
ALL
Healthy Volunteers
Yes
Istituto Auxologico Italiano IRCCS
Milan, Italy
Start Date
May 1, 2020
Primary Completion Date
December 31, 2023
Completion Date
June 30, 2024
Last Updated
September 2, 2025
220
ACTUAL participants
blood testing
OTHER
Lead Sponsor
Istituto Auxologico Italiano
NCT06927622
NCT06112340
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions